Severe autoimmune hemolytic anemia in eight patients treated with fludarabine.

Article Details

Citation
Copy to clipboard

Gonzalez H, Leblond V, Azar N, Sutton L, Gabarre J, Binet JL, Vernant JP, Dighiero G

Severe autoimmune hemolytic anemia in eight patients treated with fludarabine.

Hematol Cell Ther. 1998 Jun;40(3):113-8.

PubMed ID
9698219 [ View in PubMed
]
Abstract

We have used fludarabine to treat 36 patients with various lymphoid malignancies, including 29 with chronic lymphocytic leukemia (CLL). All these patients were heavily pretreated, and FAMP was prescribed on a compassionate basis. Eight patients (22%) developed severe autoimmune hemolytic anemia (AIHA) during or after treatment, and one died. Five patients had no previous history of hemolysis. These cases confirm the high incidence of AIHA after FAMP and suggest that the use of highly effective lymphocytotoxic agents such as fludarabine in heavily pretreated patients increases the risk of AIHA in CLL and other lymphoproliferative disorders.

DrugBank Data that Cites this Article

Drugs